Meta‐analyses of SDC1 in other contexts (e.g., COVID‐19, trauma) have similarly included smaller studies yet yielded consistent results [41], supporting its utility as a biomarker when stratified appropriately. This evidence concerns the gene SDC1 and COVID-19.